Ronald Nyberg bought $20k of GUG
director, other at Guggenheim Active Allocation Fund. 1,305 shares at an average of $15.15, traded May 5, 2025, filed May 8, 2025.
Score components
- +15RoleDirector
- 0Trade size$20k at market
- +10Relative to holdingsHoldings up 163%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-012322, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 5, 2025 | POpen-market purchase Common Stock | +1,305 | $15.15 | $20k | 2,105 | May 8, 2025 |
Related signals
Other insiders at Guggenheim Active Allocation Fund and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | GUGsell Guggenheim Active Allocation Fund | Randall C Barnes director, other | $48k 3,000 shares | -5% | |
| 18Weak | GUGbuy Guggenheim Active Allocation Fund | Ronald Nyberg director, other | $4,985 321 shares | +15% | |
| 18Weak | GUGbuy Guggenheim Active Allocation Fund | Ronald E Toupin Jr director, other | $23k 1,500 shares | +12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.